Notably, targeted degradation of CDK12/13 with YJ1206 treatment was evaluated in combination with ICB in a broad range of cancer types, including prostate cancer, melanoma, colon cancer, and lung cancer, where it significantly delays tumor growth and enhances ICB efficacy. This evidence concerns the gene CDK12 and malignant colon neoplasm.